Delivery Order SPE2DB22D2206-SPE2DB25FJB10
- Not listed
- The Defense Logistics Agency awarded a $13,963.18 delivery order to AmerisourceBergen Drug Corp for Talvey 40 mg/ml vials under a firm fixed price contract type. This delivery order, with an ultimate completion date of June 27, 2025, represents a child contract issued against the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,926.36 to AmerisourceBergen Drug Corp for TALVEY 40 mg/ml vials. This firm fixed-price, competitively awarded delivery order (Contract No. 4569329234) was issued on September 4, 2025, with an ultimate completion date of September 25, 2025. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $27,926.36 firm fixed price delivery order to AmerisourceBergen Drug Corp for TALVEY 40 mg/mL vials, with an ultimate completion date of September 2, 2025. This non-set-aside competitive award, issued on August 11, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,963.18 firm fixed-price delivery order contract is for the supply of Talvey 40 mg/ml vials. The contract has an ultimate completion date of April 30, 2025 and is not designated with a set-aside requirement. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution company. The order is for TALVEY 40 MG/ML VIALML, with a potential value of $27,225.24 and a completion date of February 2, 2024. No set-aside designation was used. AmerisourceBergen Drug Corp has an established history of providing pharmaceutical products and medical...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,963.18, is for the delivery of TALVEY 40 MG/ML VIALML medical supplies. The contract is a firm fixed-price delivery order with a completion date of July 9, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $27,926.36 firm fixed price delivery order contract is for the supply of "TALVEY 40 MG/ML VIALML" medical products. The contract has an ultimate completion date of March 6, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award, valued at $10,743.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Talvey 40 mg/mL vials. The contract is a Delivery Order, has a Firm Fixed Price pricing type, and is set to be completed by October 2, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999...
- The Defense Logistics Agency (DLA) awarded a $26,860.04 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide TALVEY 40 MG/ML VIALML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen holds with DLA to deliver a comprehensive range of medications and medical supplies to military treatment programs and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $27,225.24 firm fixed price delivery order is for the supply of Talvey 40 mg/ml vials, a pharmaceutical product. This award is associated with a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, valued up to $999,999,999.00 through December 31, 2025....
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJB10Delivery Order
The Defense Logistics Agency awarded a $13,963.18 firm fixed price delivery order to AmerisourceBergen Drug Corp for Talvey 40 mg/ml vials, with an ultimate completion date of August 14, 2025. This non-set-aside competitive award was issued on July 24, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Talvey (talquetamab) is a B-cell maturation antigen (BCMA)-targeted therapy used in the treatment of multiple myeloma, consistent with the company's portfolio of specialty medications and oncology-related pharmaceutical products delivered through federal contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.0k | 7/24/25 |